IRIS UniCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.156
AS - Asia 8.386
EU - Europa 6.446
SA - Sud America 1.994
Continente sconosciuto - Info sul continente non disponibili 466
AF - Africa 286
OC - Oceania 65
Totale 29.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.649
SG - Singapore 3.662
IT - Italia 1.956
BR - Brasile 1.626
CN - Cina 1.609
SE - Svezia 1.013
VN - Vietnam 890
DE - Germania 587
FR - Francia 580
PL - Polonia 464
GB - Regno Unito 414
BD - Bangladesh 391
IE - Irlanda 334
JP - Giappone 283
ID - Indonesia 276
HK - Hong Kong 275
FI - Finlandia 266
CA - Canada 257
IN - India 256
RU - Federazione Russa 204
MX - Messico 128
AR - Argentina 125
NL - Olanda 110
KR - Corea 102
AT - Austria 99
IQ - Iraq 88
TR - Turchia 88
ZA - Sudafrica 66
ES - Italia 64
UA - Ucraina 62
BE - Belgio 59
SA - Arabia Saudita 58
PK - Pakistan 57
CO - Colombia 53
AU - Australia 51
EC - Ecuador 46
IR - Iran 45
CH - Svizzera 41
MA - Marocco 41
VE - Venezuela 40
CZ - Repubblica Ceca 36
JO - Giordania 32
EG - Egitto 31
PY - Paraguay 30
AE - Emirati Arabi Uniti 29
PH - Filippine 29
TW - Taiwan 29
TN - Tunisia 28
CI - Costa d'Avorio 27
LT - Lituania 26
PE - Perù 26
UZ - Uzbekistan 26
CR - Costa Rica 23
MY - Malesia 22
KE - Kenya 20
IL - Israele 19
JM - Giamaica 19
UY - Uruguay 19
DZ - Algeria 17
RO - Romania 17
CL - Cile 16
PT - Portogallo 16
TT - Trinidad e Tobago 15
AZ - Azerbaigian 14
HN - Honduras 14
NZ - Nuova Zelanda 14
KZ - Kazakistan 13
NP - Nepal 13
ET - Etiopia 12
GR - Grecia 12
BO - Bolivia 11
TH - Thailandia 11
NO - Norvegia 9
AL - Albania 8
AO - Angola 8
BG - Bulgaria 8
EU - Europa 8
OM - Oman 8
SN - Senegal 8
DK - Danimarca 7
GT - Guatemala 7
HR - Croazia 7
KG - Kirghizistan 7
LB - Libano 7
MD - Moldavia 7
NI - Nicaragua 7
PA - Panama 7
BY - Bielorussia 6
LK - Sri Lanka 6
LV - Lettonia 6
NG - Nigeria 6
PR - Porto Rico 6
BZ - Belize 5
DO - Repubblica Dominicana 5
EE - Estonia 5
GA - Gabon 5
GE - Georgia 5
HU - Ungheria 5
PS - Palestinian Territory 5
RS - Serbia 5
Totale 29.264
Salva come PNG Salva come JPEG
Città #
Singapore 1.927
San Jose 1.274
Ashburn 1.247
Chandler 676
Warsaw 436
Beijing 416
Rome 405
New York 343
Fairfield 333
Dublin 331
Milan 325
Los Angeles 298
Ho Chi Minh City 295
Tokyo 242
Hong Kong 240
Jakarta 227
Dallas 219
Lauterbourg 217
Hefei 206
The Dalles 200
Wilmington 194
Hanoi 192
Helsinki 185
Houston 173
Boston 166
Chicago 164
Munich 158
Woodbridge 158
Seattle 155
Princeton 148
São Paulo 147
Frankfurt am Main 138
San Mateo 136
Council Bluffs 130
St Louis 122
Moscow 116
Ann Arbor 106
Santa Clara 100
Atlanta 98
Buffalo 97
Cambridge 95
Boardman 93
Nuremberg 92
London 79
Orem 67
Seoul 66
Toronto 65
Kent 64
North Bergen 63
Phoenix 58
Rio de Janeiro 58
Brooklyn 55
Bar Harbor 51
Tukwila 51
Denver 50
Montreal 50
Brussels 49
Paris 48
Mexico City 47
Jacksonville 46
San Francisco 45
Vienna 44
Da Nang 43
Marseille 43
Lappeenranta 41
Amsterdam 40
Washington 39
Bologna 37
Bremen 37
Shanghai 37
Stockholm 36
Augusta 34
Chennai 34
Amman 32
Johannesburg 32
Nanjing 31
Poplar 31
Baghdad 30
Dhaka 30
Düsseldorf 30
Belo Horizonte 29
Naples 29
Dearborn 28
Hyderabad 28
Mumbai 28
Redwood City 28
Turku 28
Abidjan 27
Dong Ket 27
Haiphong 27
Hải Dương 27
Manchester 26
Kish 25
Pune 25
Turin 25
Curitiba 24
Cattolica 23
Charlotte 23
Dammam 23
Hangzhou 23
Totale 15.236
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 531
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 443
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 416
Vaccines and Myocardial Injury in Patients Hospitalized for COVID-19 Infection: the CardioCOVID-Gemelli Study 396
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 348
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 343
Effect of Admilparant, an LPA1 Antagonist, on Disease Progression in Pulmonary Fibrosis 342
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 332
Best Practice: International Multisociety Consensus Statement for Post-COVID-19 Residual Abnormalities on Chest CT Scans 303
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 258
The Role of Inflammation and Fibrosis in ILD Treatment Decisions 251
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 244
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment 241
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 237
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 222
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 217
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 216
COVID-19 atypical Parsonage-Turner syndrome: a case report 212
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial 211
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 209
Malnutrition in COVID-19 survivors: prevalence and risk factors 207
A real-time integrated framework to support clinical decision making for covid-19 patients 207
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis 204
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 204
Assessment of neurological manifestations in hospitalized patients with COVID-19 203
Residual respiratory impairment after COVID-19 pneumonia 199
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 194
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey 193
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 193
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 191
Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry 187
Malnutrition in COVID-19 survivors: prevalence and risk factors 185
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 185
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 181
Residual respiratory impairment after COVID-19 pneumonia 181
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 179
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society 178
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 177
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 174
Sarilumab use in severe SARS-CoV-2 pneumonia 170
Reply to Moodley and to Ravaglia et al 169
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 169
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 167
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 165
The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey 162
Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series 157
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 156
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 155
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 154
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 152
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 151
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 150
Nerandomilast in Patients with Progressive Pulmonary Fibrosis 146
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 145
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis 144
Case of a 33-Year-Old Woman With Hemoptysis and Migrant Nodular Cavitary Lesions 144
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 143
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 143
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 139
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 139
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 136
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 136
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 135
Severe asthma: One disease and multiple definitions 135
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 134
Reliability of crackles in fibrotic interstitial lung disease: a prospective, longitudinal study 133
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 132
Promising advances in treatments for the management of idiopathic pulmonary fibrosis 131
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 131
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 130
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 129
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 129
Antibody-based therapies for idiopathic pulmonary fibrosis 127
Idiopathic pulmonary fibrosis 125
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS®trials 125
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 125
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 123
A randomized trial of pamrevlumab in patients with COVID-19 pneumonia 122
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 122
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 122
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 122
Antibody-based therapies for idiopathic pulmonary fibrosis 122
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 122
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants 120
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression 120
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 120
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 119
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis 118
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years 115
Reticulation is a Risk Factor of Progressive Subpleural non-Fibrotic Interstitial Lung Abnormalities 115
Current and Future Idiopathic Pulmonary Fibrosis Therapy 113
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 112
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 112
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 112
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 112
CC-90001, a c-Jun N-Terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: Design of a phase 2, randomised, placebo-controlled trial 112
Novel insights in fibrotic pulmonary sarcoidosis 111
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study 111
Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative 110
Statin therapy and lung disorders 109
Totale 17.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.265
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.265
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.365 0 75 29 155 56 48 30 237 61 68 339 267
2022/20232.924 315 302 274 430 270 355 136 179 310 147 132 74
2023/20242.037 69 436 91 100 102 211 136 75 90 149 234 344
2024/20254.633 121 97 362 202 306 208 220 229 751 411 923 803
2025/202613.644 1.672 551 971 1.706 2.025 630 1.974 695 937 922 672 889
2026/20272.809 696 2.113 0 0 0 0 0 0 0 0 0 0
Totale 29.799